Omnicell, Inc. (NASDAQ:OMCL) shares gained 4.19% in premarket trading Thursday after the healthcare technology company delivered better-than-expected third-quarter results and lifted its full-year guidance on the back of strong demand for its connected medication management systems.
The company reported adjusted earnings of $0.51 per share, well above the analyst estimate of $0.36, while revenue reached $310.63 million, exceeding the consensus forecast of $295.6 million and marking a 10% year-over-year increase.
“We are pleased with the strong financial performance delivered in the third quarter, with total revenues, non-GAAP EBITDA and non-GAAP EPS all exceeding the upper end of our previously issued guidance,” said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell.
Omnicell credited its performance to continued strength in its flagship point-of-care automation devices, which remain the company’s largest revenue contributor. Additional gains came from its technical services, consumables, and software-as-a-service (SaaS) offerings, underscoring the growing demand for digital healthcare automation solutions.
Non-GAAP EBITDA rose to $41 million for the quarter, slightly above the $39 million recorded in the prior-year period.
Looking ahead, Omnicell expects fourth-quarter revenue between $306 million and $316 million, topping the analyst consensus of $295.3 million, and adjusted earnings between $0.40 and $0.50 per share. The company also raised its full-year 2025 earnings outlook to $1.63–$1.73 per share, up from prior guidance and ahead of the $1.55 analyst estimate.
During the quarter, Omnicell retired the remaining $175 million principal balance of its convertible senior notes that matured in September and repurchased roughly 1.99 million shares of common stock for about $62 million.
The company also reported $28 million in operating cash flow, up from $23 million a year earlier, ending the quarter with $180 million in cash and equivalents and total debt of $167 million.